#### 1 Field study to determine the reliability of HIV viral load results shows minimal impact of delayed

- 2 testing.
- 3 Diana Hardie<sup>\*1,2</sup>, Howard Newman<sup>2</sup>, Joanna Ried<sup>2,3</sup>, Nei-Yuan Hsiao<sup>1,2</sup>, Gert van Zyl<sup>2,3</sup>, Lucia Hans<sup>4,5</sup>,
- 4 Jasantha Odayar<sup>6</sup>, Stephen Korsman<sup>1,2</sup>
- <sup>1</sup> Division of Medical Virology, Department of Pathology, University of Cape Town, Cape Town, South
- 6 Africa
- 7 <sup>2</sup> National Health Laboratory Service, Johannesburg, South Africa
- 8 <sup>3</sup> Division of Medical Virology, University of Stellenbosch, Cape Town, South Africa.
- 9<sup>4</sup> National Health Laboratory Service, National Priority Programme (NPP), Johannesburg, South Africa
- <sup>5</sup> Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of
- 11 Witwatersrand, Johannesburg, 2193, South Africa
- <sup>6</sup> Division of Epidemiology & Biostatistics, School of Public Health, University of Cape Town, Cape Town,
- 13 South Africa
- 14 \*Diana Hardie
- 15 <u>Diana.hardie@uct.ac.za</u>
- 16

17

# 18 Abstract:

19 Understanding factors that impact on the accuracy of HIV viral load (VL) results is key to quality 20 improvements of VL programmes, particularly in resource limited settings. In this study we evaluated 21 whether testing delay and room temperature storage (between 25-30°C) prior to testing affected 22 results. 249 individuals who were on antiretroviral therapy, or with newly diagnosed HIV, were 23 recruited and three PPT samples were collected from each patient. One sample was tested within 24 24 hours, while the others were stored un-centrifuged at ambient temperature prior to testing. 25 Centrifugation and testing of matched samples were performed on days 4 and 7 after collection. In 26 samples with initial VL >2 log copies/mL, time delay and ambient temperature storage had minimal 27 impact. When grouped according to day 1 VL range, 96-100% of samples at day 4 and 93-100% at day 7 28 had a VL within 0.5 log copies/mL of the first result. Greatest variability was observed at day 4 and 7 29 when the day 1 VL was <2 log copies/mL, however, there was no trend of increasing difference with 30 time. Of day 1 samples with undetectable VL or VL <50copies/mL, 80% and 78% had concordant results 31 at days 4 and 7, respectively. Detection in later samples appeared to be stochastic, rather than 32 showing a worsening trend. These results provide further evidence that VL is stable in PPT tubes for up 33 to 7 days when stored at room temperature. It shows that there is significant variability in samples with 34 VL close to the limit of detection, not affected by testing delay. Stochastic variation or technical factors that may increase the chance of false positive results could possibly account for this. 35

## 36 Introduction

Viral load (VL) testing is a key element to reaching and monitoring progress towards the UNAIDS
95:95:95 targets(1). This reflects ensuring that HIV-infected patients are diagnosed, started on antiretroviral therapy (ART) and are virologically suppressed. South Africa (SA) has the world's largest
treatment program with > 6 million people living with HIV (PLWH) enrolled(2). Over 6 million viral loads
were performed by public sector laboratories in SA in 2022(3). However, logistics and pre-analytical
challenges such as transporting, registering, centrifuging and storing samples could compromise the
quality of testing.

Currently manufacturers of high throughput VL platforms such as Roche Molecular Systems (Pleasanton,
 USA) and Abbott Laboratories (Chicago, USA) recommend that whole blood samples should be

centrifuged within 6 to 24 hours of collection and plasma should either be frozen at - 80 °C or tested 46 47 within 5 days of sample collection(4)(5). Transporting samples to the laboratory for separation into 48 plasma is often not achievable within the official manufacturer time constraints in resource-limited 49 settings. Samples may reach the laboratory more than 24 hours after collection and are stored at 4°C in 50 their primary tubes until testing. The extent to which these pre-analytical factors compromise the 51 accuracy of results was assessed in two laboratory simulation studies (6)(7) and a systematic review (8). 52 All three showed good preservation of viral RNA beyond the currently recommended testing time. This 53 finding was confirmed in a local study performed at Groote Schuur Hospital in which routine diagnostic 54 samples collected in ethylenediaminetetraacetic acid (EDTA) tubes or EDTA-plasma preparation tubes 55 (PPT) were stored after initial HIV VL testing at a range of times and storage temperatures(9). The VL in 56 samples stored for up to a week reliably differentiated between ART-suppressed and failing patients in 57 98.8% of instances(9). However, samples had already been centrifuged prior to storage and the study 58 was performed entirely in the laboratory environment. In addition, it was only possible to follow trends 59 in VL from the same patient over 2 time points due to sample volume constraints. In this current study, 60 we evaluated the extent to which testing delay and adverse sample storage affects VL by testing serial samples from the same patients at different time points after sample collection. 61

### 62 Study objectives:

To determine the impact of testing delay on the accuracy of HIV RNA quantification in diagnostic
 specimens collected and stored in un-centrifuged PPT tubes.

- To describe the impact of storage at a warmer ambient temperature (storage between 25-30°C)
   on the precision of HIV RNA quantification in diagnostic samples in un-centrifuged PPT tubes.
- To determine whether centrifugation prior to storage improves the precision of results in
   samples where testing is delayed and whether omitting a 2<sup>nd</sup> re-centrifugation step prior to
   delayed testing affects precision (evaluated at one site, namely GSH).

## 70 Methods:

71 Ethical approval for the study was obtained from the Human Subjects Research Ethics Committee of the

72 Faculty of Health sciences at the University of Cape Town (HREC Ref 159/2019). Written informed

consent was obtained from all participants prior to enrolment. Only individuals older than 18 years were

74 recruited.

Enrolment for 2 sites (PE and TBH) began on 21 November and 5 December 2019 and ended on 24
January and 23 January 2020, respectively. Enrolment for the 3<sup>rd</sup> site (GSH) began on 28 August 2022
and ended on 6 June 2023 (following normalisation of laboratory services after SARS-CoV-2 pandemic).

78 The study was performed at three sites within the National Health Laboratory Service (NHLS) network of 79 HIV VL testing laboratories. Patients were recruited from four ARV clinics, three in the Cape Metro and 80 one in the Eastern Cape Province of South Africa. Patients who were due to have a VL test or who were 81 newly diagnosed and not yet on therapy, were approached and asked to give two extra blood tubes for 82 HIV VL testing. Three PPT samples were collected during the same blood draw and delivered to the 83 regional HIV VL testing laboratory. On arrival, one sample was centrifuged and sent for immediate HIV 84 VL testing. Testing was completed within 24 hours of sample collection. The result from this test was 85 issued for routine patient management. The other two tubes were stored un-centrifuged in routine 86 field conditions where the temperature varied between 25-30°C. Four days after sample collection, one 87 of the stored samples was centrifuged and a VL test was performed. Seven days after sample collection, the third tube was centrifuged and tested. VL testing was performed using the routine assay in each of 88 89 the three participating laboratories at the time of study, namely Roche CAP/CTM (Tygerberg laboratory), 90 Roche 6800 (Port Elizabeth laboratory) and Abbott Alinity m (Groote Schuur laboratory). The study plan 91 is given in Fig 1.

#### 92 Fig 1 Study plan:

On a subset of patients (done at Groote Schuur laboratory only), HIV VL was repeated at day 7 on the sample that had been centrifuged and tested on day one. The day 1 centrifuged samples were stored under the same conditions as the yet untested samples, prior to repeat testing. The samples were not re-centrifuged prior to repeat testing on day 7. They were used to assess whether storage in an already centrifuged state improved stability of VL in the sample.

VL data from days 1, 4 and 7 testing were extracted from the laboratory information system and
analysed using Bland-Altman plots (10).

For analysis, unless otherwise specified, samples with a VL that was lower than the limit of detection (LDL) were assigned a value of "1" (0 log) copies/mL. Samples with a VL value of <20 copies/mL, were assigned a value of "19" (1.28 log) copies/mL, otherwise the log value of the reading in copies/mL was used for analysis.

- 104 A difference in VL of >0.5 log copies/mL was considered significant and likely to reflect a change that
- 105 was caused by factors other than random expected variation. (11)

106

# 107 **Results:**

- 108 A total of 249 patients were consented and provided 3 PPT samples for testing (51 from Tygerberg, 60
- 109 from Port Elizabeth (PE) and 138 from Groote Schuur (GSH). Samples from 6 patients arrived at the
- 110 laboratory more than 24 hours after collection and these patients were excluded from the study.
- 111 Day 1 VLs segregated into the following VL categories: 55 (22.6%) were LDL, 46 (18.9%) were
- 112 detectable, but <50 copies/mL, 7 (2.9%) were 50-100 copies/mL, 28 (11.5%) were 2-3 log copies/mL, 30
- 113 (12.3%) were 3-4log copies/mL, 36 (14.8%) were 4-5log copies/mL, 30 (12.3%) were 5-6log copies/mL
- 114 and 11 (4.5%) were >6 log copies/mL.
- 115Table 1: Proportion of samples tested on day 4 and 7 within 0.3 and 0.5 log copies/mL of day 1 viral

### 116 load value by day 1 VL category:

Day 1 viral	Number of	Day 4 viral	Day 4 viral	Day 7 viral	Day 7 viral			
category	Samples	0.3 log of day	0.5 log of day	0.3 log of day	0.5 log of day			
0,		1 result	1 result	1 result	1 result			
LDL	55	51%	51%	60%	60%			
<log2< th=""><th>53</th><th>51%</th><th>60%</th><th>55%</th><th>62%</th></log2<>	53	51%	60%	55%	62%			
Log2-3	27	89%	96%	81%	93%			
Log3-4	30	87%	97%	87%	97%			
Log4-5	36	81%	100%	86%	97%			
Log5-6	30	93%	97%	97%	97%			
>log6	11	73%	100%	91%	100%			

117

### 118 Viral load stability at day 4 and 7:

- 119 Bland-Altman plots were used to evaluate differences in day 1 vs day 4 VL results and between day 1
- 120 and day 7(10). Overall, there was very little difference in paired readings at both day 4 and day 7
- 121 compared with day 1. The mean bias at day 4 was -0.15 and for day 7 was -0.12 log copies per mL,
- indicating a lower reading in the samples where testing was delayed, but the decay was minimal (Fig 2).
- 123 For samples with an initial VL of >2 log copies/mL, the paired VL value at day 4 and day 7 was within 0.5

log copies/mL in 96-100% of instances for day 4 and 93-100% of instances for day 7 (table 1), signifying 124 125 minimal impact of the testing delay on the quantification. The greatest variation was observed for 126 samples with day 1 VLs less than 2 log copies/mL, with only 60% of samples at day 4 and 62% at day 7 127 having a repeat viral load within 0.5 log copies/mL. In this very low viraemic range, even though many of the changes were >0.5 log copies/mL, the difference in quantification does not reflect real clinically 128 129 significant differences in VL value. No clinical action would be indicated for results in this (<2 log copies/mL) range(12)(13). Indeed, in the 101 samples with a day 1 viral load below 50 copies/mL, 80% 130 remained <50 copies/ml at the day 4 test and 78% at the day 7 test. 131

132

133Figure 2: Variability of all paired VL results at day 4 and 7: Bland-Altman plots of day1 vs day4 VL (a)134and day1 vs day7 (b) show negative bias of -0,14 log copies/mL at day4 and -0,12 log copies/mL at day

135 **7**, with greatest variability at lower day 1 VL (<2logcopies/mL). Green lines represent + and -2SD and

red dotted line the mean difference in HIV viral load on Bland Altman plots. Histograms of paired VL

differences at day 4 and 7 are shown in(c) and (d). The peaks at -1.2 to -0.9 and +0.9 to 1.2 mostly reflect samples with VLs that were <1.3 log copies/mL which transitioned to LDL or LDL samples that</p>

139 transitioned to <1.3log copies/mL.

140

## 141 Viral load precision between 100-1000 copies/mL (2-3 log copies/mL):

142 27 samples had day 1 VL values between 100 and 1000 copies per mL. Variability was much less, with

143 96% of samples on day 4 and 93% on day 7 having VL within 0.5 log copies/mL. The box and whisker

144 plot (Fig 3a) which included all samples with quantifiable VL from 20-1000 copies/mL show the

145 overlapping VL ranges at day 1, 4 and 7, with occasional outlier values.

146

147

Figure 3: Viral load changes in samples with day 1 viral load between 1.3-3 log copies/mL: (a) shows a box and whisker plot comparing viral load ranges at 1, 4 and 7 days. Histograms in (b) and (c) show

150 the variation in paired samples at day 4 and 7.

151

#### 152 Day 1 undetectable/<50 copies/mL samples that became detectable on repeat

#### 153 testing:

- 154 In total, 18 patients who had viral loads <50 copies/mL at day 1 had a repeat viral load of >2 log
- 155 copies/mL at day 4 or day 7 (Fig 4a) and of these, 8 were >2 log copies/mL at both time points.
- 156 Detection in a later sample appeared to be stochastic. There was no trend to suggest that this
- 157 phenomenon worsened with time. The testing site or automated technology used to perform testing
- seemed to be an important factor as this varied from 0% (GSH, Abbott Alinity), 11% and 22% at days 4
- and 7 (Tygerberg, Roche CAP/CTM) to 50% (PE, Roche Cobas 6800). (Fig 4b)

160

161 Figure 4 (a) shows the number and viral load ranges on days 4 and 7 of samples that were day 1 LDL or

162 had values <50 copies/mL which became detectable on repeat testing and (b) shows the proportion of

samples with day 1 viral loads of LDL or <50 copies/mL that had a VL >2 log copies/ml on repeat

164 testing, by testing site/technology used.

Patients with a day 1 VL of detectable, but <20, were 2.3 times more likely to have a detectable VL at</li>
day 4 and 1.8 times more likely to have a detectable VL at day 7 than patients with an undetectable day
1 VL (LDL).

168

### 169 Stability in centrifuged samples:

VL stability in samples that were centrifuged on day 1 and (re-) tested on day 7 was also analysed in a subset of 103 samples from one centre (GSH). The day 1 sample was stored after initial testing under the same conditions as the un-centrifuged samples and was retested on day 7 (without recentrifugation). The VL values on day 1 and 7 were very similar (**Fig 5**). The mean difference in VL between day 1 and day 7 was 0.03 log copies/mL and SD was narrower at 0.42 than for the samples that were first centrifuged and tested on day 7. No samples had a clinically significant change in VL when comparing the day 1 and day 7 samples. One sample had an initial VL of 4.95 log copies/mL which

177 changed to 3.85 log copies/mL. Thus, there was only one result in this group with a clinically significant

178 (-1.1 log copies/mL) VL change. The good results in this experiment could reflect: better sample

179 preservation during storage when sample is separated on day 1, lack of viral RNA leakage in the PPT

tubes on storage (previously flagged as a potential problem (14)(15)) or other technical factors relatingto the testing site.

182

Figure 5: Variability of paired viral loads of day 1 samples that were re-run on day 7: (a) Bland Altman
 plot reveals minimal bias and lower variance in day 1 vs day 7 results. Green lines represent + and 2SD and the red dotted line the mean difference in HIV viral load. Histogram in (b) shows the
 difference in day 1 and 7 viral load results.

## 187 **Discussion:**

188 Various factors impact on the accuracy of HIV VL test results (lucia's paper) and an understanding of 189 these is key to better interpretation of the result and mitigation of potential inaccuracies. In this study 190 we found that delay of testing for the first 7 days had minimal effect on test results. This was clearly 191 shown for samples with an initial VL >2 logs. Testing of paired samples at day 4 and 7 returned 192 equivalent results in 96-100% (at day 4) and 93-100% (at day 7) of instances when stratified by VL level 193 at day 1 (sample tested within 24 hours of collection). These findings are compatible with previous work 194 done by ourselves (9) and a systematic review by Bonner et al (8) which showed that VL was stable 195 when samples are stored under laboratory conditions for up to 7 days. However, here we provide 196 additional field data on the stability of samples with a day 1 VL below 3 log copies/mL and also show 197 that storage of samples in an un-centrifuged state are stable when stored at ambient temperatures 198 between 25 and 30°C for up to 7 days. This more closely matches the real-world situation, especially in 199 low-and-middle-income countries with high HIV disease burdens and large antiretroviral treatment 200 programmes such as in SA. Under these conditions testing is often delayed due to logistical issues, 201 especially in remote rural areas, and these results provide reassurance that time delay is not a major 202 cause of result inaccuracies.

Significant variability was observed in samples with day 1 VLs of <2log, with only 60% (on day 4) and 62%</li>
(on day 7) of samples having repeat VL values within 0.5 log copies/mL. But factors other than time
delay are more likely responsible. Variability in logarithmic terms near the limit of detection is expected
to be greater because at this level, detection/loss of detection and outlier results will represent a bigger
logarithmic change(16). Clinicians should be aware of the inherent VL variability in this range and
interpret results with caution.

Both local and international guidelines advise using VL levels of <50 copies/mL to reflect viral</li>
suppression in patients on antiretroviral therapy (ART) (12)(17) and it was reassuring that for samples
with a day 1 VL in this range, 80% at day 4 and 78% at day 7 remained in this category on repeat testing.
Nonetheless, recent studies have highlighted the diagnostic importance of persistent low level viraemia
in patients on ART as a marker of increased risk of virological failure(18,19) and a better understanding
of the cause of these low positive results is needed.

Low VLs could also result from detection of intra-cellular viral nucleic acids in stored samples (12,13).

216 Sometimes cellular material remains above the gel in PPT tubes after centrifugation (15) and aspiration

217 during the testing process can falsely elevate the VL in recently suppressed individuals(20). This

218 phenomenon is only likely to make a difference if the plasma VL is very low or undetectable to start off

with. This could account for some of the 20% of patients who had suppressed (<50 copies/mL) day 1

220 VLs, that were detectable in day 4 or 7 samples. Of note, samples from patients that were detectable,

but VL was <20 copies/mL at day 1, were twice as likely to have a detectable VL in a stored sample than

patients that had an undetectable VL at day 1.

223 Noteworthy was the observation that the proportion of samples affected, varied markedly at the

224 different testing sites. Technical factors such as duration and speed of centrifugation of primary

samples, the method of sample aspiration by the auto-analyser or other undefined laboratory factors

226 could increase false reactivity during the testing process. Re-centrifugation immediately prior to testing

has been recommended (15) as a means to reduce false reactivity in stored samples, the rationale is that

cellular elements containing viral nucleic acids may diffuse into the plasma when storage is prolonged.

229 In the subset of 103 patients evaluated, re-centrifugation was omitted when the sample first tested on

230 day 1 was rerun on day 7. Interestingly, no samples had a clinically significant change in VL when

comparing the day 1 and day 7 samples. This result was reassuring. A caveat is that this experiment

was only done at the site where there was very low variability in the stored samples anyway.

### 233 Limitations:

Only three samples were collected from each patient, and this limited the number of factors we could evaluate. Testing occurred across 3 sites and different testing platforms could have accounted for some of the differences that were seen, for example, a much lower rate of detectable viral load in later samples with day 1 suppressed VL at one site. In the LMIC context where samples may arrive for testing

- after transport at temperatures above 30°C and in EDTA tubes without gel separator, more evaluation is
   needed to define the limits of acceptable pre-analytical conditions.
- 240

#### 241 **Conclusion:**

- 242 Our field study provides further evidence that time delay had minimal impact on viral load quantification when samples were stored at room temperature. When the D1, D4 and D7 results were compared, 243 244 substantial variability was observed in samples with VLs close to the limit of detection, but there was no 245 trend to suggest increasing variance with time. Some samples with negligible VL at day 1 had detectable 246 VL on samples tested later and this was more likely to happen when the day 1 plasma VL was <20 rather 247 than LDL. The most likely explanation is that this reflects a combination of stochastic variation and false 248 detection of low level viraemia during the testing process. The variation observed near the limit of assay 249 detection could also contribute to the phenomenon of viral blips. The contribution of other patient-
- 250 related and technical issues requires further investigation.

### 251 **References:**

- FAST-TRACK Ending the AIDS Epidemic by 2030. UNAIDS Publ [Internet]. 2014;(1):1–14. Available
   from: https://www.unaids.org/sites/default/files/media\_asset/JC2686\_WAD2014report\_en.pdf
- 254 2. NHLS Annual report 2017/18 [Internet]. 2018. p. 71–5. Available from:
- 255 http://intranet.nhls.ac.za/assets/files/policy/NHLS\_AR\_2018.pdf
- 256 3. Hans L, Cassim N, Sarang S, Hardie D, Ndlovu S, Venter WDF, et al. HIV Viral Load Testing in the
- 257 South African Public Health Setting in the Context of Evolving ART Guidelines and Advances in
- 258 Technology , 2013 2022. Diagnostics [Internet]. 2023;13(17):2013–22. Available from:
- 259 https://doi.org/10.3390/diagnostics13172731
- 260 4. Abbott RealTime HIV1 kit insert 51-602100/R10 [Internet]. 2014. Available from:
- 261 https://www.who.int/diagnostics\_laboratory/evaluations/pq-list/hiv-
- 262 vrl/160530\_0145\_027\_00\_final\_public\_report\_v2.pdf
- 263 5. Roche CAP/CTM HIV-1 v2.0 EXPT-IVD [Internet]. 2018. Available from: https://pim-
- 264 eservices.roche.com/eLD\_SF/za/en/Documents/GetDocument?documentId=ab57160e-0bd6-
- 265 e811-df87-00215a9b3428

266	6.	Vandamme AM, Van Laethem K, Schmit JC, Van Wijngaerden E, Reynders M, Debyser Z, et al.
267		Long-term stability of human immunodeficiency virus viral load and infectivity in whole blood.
268		Eur J Clin Invest. 1999;29(5):445–52. available from https://doi.org/10.1046/j.1365-
269		2362.1999.00462.x
270	7.	Amellal B, Murphy R, Maiga A, Brucker G, Katlama C, Calvez V, et al. Stability of HIV RNA in
271		plasma specimens stored at different temperatures. HIV Med. 2008;9(9):790–3. available from
272		https://doi.org/ 10.1111/j.1468-1293.2008.00632.x
273	8.	Bonner K, Siemieniuk RA, Boozary A, Roberts T, Fajardo E, Cohn J. Expanding access to HIV viral
274		load testing: A systematic review of RNA stability in EDTA tubes and PPT beyond current time and
275		temperature thresholds. PLoS One. 2014;9(12):1–13. available from https://
276		doi.org/10.1371/journal.pone.0113813
277	9.	Hardie D, Korsman S, Ameer S, Vojnov L, Hsiao NY. Reliability of plasma HIV viral load testing
278		beyond 24 hours: Insights gained from a study in a routine diagnostic laboratory. PLoS One.
279		2019;14(7):1–12. available from https://doi.org 10.1371/journal.pone.0219381/
280	10.	Giavarina D. Understanding Bland Altman analysis. Biochem Medica. 2015;25(2):141–51.
281		available from https://doi.org/ 10.11613/BM.2015.015
282	11.	Douglas Wilson, Sudeshni Naidoo, Linda-Gail Bekker, Mark Cotton GM. Handbook of HIV
283		Medicine. 1st ed. Douglas Wilson, Sudeshni Naidoo, Linda-Gail Bekker, Mark Cotton GM, editor.
284		Oxford New York: Oxford University Press, South Africa; 2002. 44–46 p.
285	12.	Jeremy Nel, Graeme Meintjes, Regina Osih (Chairpersons), Larisse Badenhorst, John Black, Rosie
286		Burton, Nomathemba Chandiwana, Francesca Conradie, Natasha Davies, Mariam Edoo, Ute
287		Feucht, Cloete Jansen Van Vuuren, John Joska, Richard Lessells, Gary Maartens, Pheto Mangena,
288		Thandekile Manzini, Yunus Moosa, Ndiviwe Mphothulo, Jennifer Nash, Dulcy Rakumakoe, Evan
289		Shoul, Phumla Sinxadi, David Spencer, Helen van der Plas, Camilla Wattrus, Jeannette Wessels,
290		Joana Woods, Jarrod Zamparini. SOUTHERN AFRICAN HIV CLINICIANS SOCIETY GUIDELINES FOR
291		ANTIRETROVIRAL THERAPY IN ADULTS : 2023 UPDATE A publication of the Southern African HIV
292		Clinicians Society. 2023; available at http://www.sahivsoc.org
293	13.	World Health Organization. CONSOLIDATED GUIDELINES ON HIV PREVENTION, TESTING,
294		DELIVERY AND MONITORING: TREATMENT, SERVICE RECOMMENDATIONS FOR A PUBLIC HEALTH

295 APPROACH. Geneva: WHO; 2021.

- 296 14. Kran AMB, Jonassen TØ, Sannes M, Jakobsen K, Lind A, Mæland A, et al. Overestimation of 297 human immunodeficiency virus type 1 load caused by the presence of cells in plasma from 298 plasma preparation tubes. J Clin Microbiol. 2009;47(7):2170–4. available at http://doi.org/ 299 10.1128/JCM.00519-09 300 15. Procop GW, Taege AJ, Starkey C, Tungsiripat M, Warner D, Schold JD, et al. Preanalytic process 301 linked to spuriously elevated HIV viral loads: improvement on an FDA-approved process. Diagn 302 Microbiol Infect Dis. 2017;89(1):44-6. available at http://doi.org 303 10.1016/j.diagmicrobio.2016.09.003 304 16. Cobb BR, Vaks JE, Do T, Vilchez RA. Evolution in the sensitivity of quantitative HIV-1 viral load tests. J Clin Virol [Internet]. 2011;52(SUPPL. 1):S77–82. Available from: 305 306 http://dx.doi.org/10.1016/j.jcv.2011.09.015 307 17. Ellman TM, Alemayehu B, Abrams EJ, Arpadi S, Howard AA, El-Sadr WM. Selecting a viral load 308 threshold for routine monitoring in resource-limited settings: Optimizing individual health and 309 population impact: Optimizing. J Int AIDS Soc. 2017;20:16–8. available from http://doi.org/ 10.1002/jia2.25007 310 311 18. Chun HM, Abutu A, Milligan K, Ehoche A, Shiraishi RW, Odafe S, et al. Low-level viraemia among 312 people living with HIV in Nigeria: a retrospective longitudinal cohort study. Lancet Glob Heal. 2022;10(12):e1815-24. available from http://doi.org/ 10.1016/S2214-109X(22)00413-2 313 314 19. Crespo-Bermejo C, de Arellano ER, Lara-Aguilar V, Valle-Millares D, Gómez-Lus ML, Madrid R, et al. Persistent low-Level viremia in persons living with HIV undertreatment: An unresolved status. 315 316 Virulence [Internet]. 2021;12(1):2919–31. Available from: https://doi.org/10.1080/21505594.2021.2004743 317 318 20. Golob JL, Stern J, Holte S, Kitahata MM, Crane HM, Coombs RW, et al. HIV DNA levels and decay 319 in a cohort of 111 long-term virally suppressed patients. Aids [Internet]. 2018; (January):1. 320 Available from: http://insights.ovid.com/crossref?an=00002030-900000000-97148
  - 321

322 Supporting information:

323 S1 File\_XLS: Raw data file containing day 1, 4 and 7 viral load results of study samples.



\*Subset: n=103, tube 1 retested on day 7







Viral load log 1.3–3 copies/ml: day 7

14												14										
12																						
10																						
8													7									
6																						
4								4														
4									2	2												
2	0	0	0	0	0	1	0							1	0	0	0	0	0	0	0	0
0	(eo ' -3)	[-3, -2.7]	[-2.7, -2.4)	[-2.4, -2.1)	[-2.1, -1.8]	[-1.8, -1.5)	[-1.5, -1.2)	[-1.2, -0.9)	(9.0- '6.0-]	[-0.6, -0.3)	[-0.3, 0)	(0, 0.3)	[0.3 , 0.6)	[0.6 , 0.9)	[0.9 , 1.2)	[1.2 , 1.5]	[1.5 , 1.8)	[1.8, 2.1)	[2.1, 2.4)	[2.4, 2.7]	[2.7,3]	[3.0,∞)
	Day 7																					





Day 1 vs day 7R



Range of log difference from day 1 (day 1 minus day 7)